AbbVie
American pharmaceutical company
Updates & Highlights
The Motley Fool · about 9 hours ago
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?
Fierce Pharma · about 16 hours ago
AbbVie’s Skyrizi retakes edge in pharma’s July ad spending league
Новости GxP · about 17 hours ago
AbbVie’s Elahere wins Russian approval for ovarian, fallopian tube and peritoneal cancer
Recent Openings
View all 1 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Health Insurance
Medical, dental & vision
Learning Budget
Professional development
Generous PTO
Paid time off
Competitive Salary
Market-rate compensation
Equity/Stock Options
Ownership in the company
Remote Work
Work from anywhere flexibility
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at AbbVie?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentAbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool · about 9 hours ago
AbbVie’s Skyrizi retakes edge in pharma’s July ad spending league
AbbVie’s Skyrizi retakes edge in pharma’s July ad spending league
Fierce Pharma · about 16 hours ago
AbbVie’s Elahere wins Russian approval for ovarian, fallopian tube and peritoneal cancer
AbbVie’s Elahere wins Russian approval for ovarian, fallopian tube and peritoneal cancer
Новости GxP · about 17 hours ago
AbbVie (ABBV) Q1 2026 Earnings Call Transcript
AbbVie (ABBV) Q1 2026 Earnings Call Transcript
Fortune · about 20 hours ago
The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call
The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call
StockStory · about 21 hours ago
South Korean company seeks to challenge AbbVie with fat‑derived bio‑scaffold for facial rejuvenation
South Korean company seeks to challenge AbbVie with fat‑derived bio‑scaffold for facial rejuvenation
Новости GxP · about 21 hours ago
Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts
Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts
STAT · 1 day ago
Prediction: AbbVie Will End The Year at This Price
Prediction: AbbVie Will End The Year at This Price
24/7 Wall St. · 3 days ago
Prediction: AbbVie Will End The Year at This Price
Prediction: AbbVie Will End The Year at This Price
Yahoo Finance · 3 days ago
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
Yahoo Finance · 3 days ago
AbbVie Seeks at Least $8 Billion in Debt to Fund Apogee Deal
AbbVie Seeks at Least $8 Billion in Debt to Fund Apogee Deal
Bloomberg.com · 3 days ago
AbbVie (ABBV) Q2 2026 Earnings Call Transcript
AbbVie (ABBV) Q2 2026 Earnings Call Transcript
The Motley Fool · 4 days ago
AbbVie’s Growth Now Leans On A Single Molecule
AbbVie’s Growth Now Leans On A Single Molecule
Trefis · 4 days ago
AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says
AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says
Yahoo Finance · 5 days ago
AbbVie Earnings: Maintaining Our Fair Value Estimate Following a Steady Second Quarter
AbbVie Earnings: Maintaining Our Fair Value Estimate Following a Steady Second Quarter
Morningstar · 5 days ago
AbbVie: Strong Q2 And New Catalysts Keep Me Bullish (NYSE:ABBV)
AbbVie: Strong Q2 And New Catalysts Keep Me Bullish (NYSE:ABBV)
Seeking Alpha · 5 days ago
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates
Reuters · 8 days ago
AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market
AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market
Fierce Pharma · 8 days ago
AbbVie Sales Beat Estimates as Botox Shows Signs of Revival
AbbVie Sales Beat Estimates as Botox Shows Signs of Revival
Bloomberg.com · 8 days ago
AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps
AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps
WSJ · 8 days ago